Brilinta FDA Approval History
Last updated by Judith Stewart, BPharm on Nov 12, 2020.
FDA Approved: Yes (First approved July 20, 2011)Brilinta
Brand name: Brilinta
Generic name: ticagrelor
Dosage form: Tablets
Treatment for: Acute Coronary Syndrome, Coronary Artery Disease, Cardiovascular Risk Reduction, Ischemic Stroke, Prophylaxis
(ticagrelor) is a P2Y12
platelet inhibitor indicated:
- to reduce the risk of cardiovascular (CV) death, myocardial infarction (MI), and stroke in patients with acute coronary syndrome (ACS) or a history of MI. For at least the first 12 months following ACS, it is superior to clopidogrel.
Brilinta also reduces the risk of stent thrombosis in patients who have been stented for treatment of ACS.
- to reduce the risk of a first MI or stroke in patients with coronary artery disease (CAD) at high risk for such events. While use is not limited to this setting, the efficacy of Brilinta was established in a population with type 2 diabetes mellitus (T2DM).
- to reduce the risk of stroke in patients with acute ischemic stroke (NIH
Stroke Scale score ≤5) or high-risk transient ischemic attack (TIA).
Development timeline for Brilinta
|Nov 6, 2020||Approval Brilinta Approved in the US to Reduce the Risk of Stroke in Patients with an Acute Ischemic Stroke or High-Risk Transient Ischemic Attack|
|Jun 1, 2020||Approval Brilinta Approved in the US to Reduce the Risk of a First Heart Attack or Stroke in High-Risk Patients with Coronary Artery Disease|
|Sep 3, 2015||Approval FDA Approves Expanded Indication for Brilinta to Include Long-Term Use in Patients with a History of Heart Attack|
|Mar 30, 2015||Approval FDA Approves New Crushing Option for the Administration of Brilinta|
|Jul 20, 2011||Approval FDA approves blood-thinning drug Brilinta to treat acute coronary syndromes|
|Feb 4, 2011||US FDA Assigns New PDUFA Date for Brilinta (ticagrelor tablets)|
|Jan 21, 2011||AstraZeneca Replies to the US FDA Complete Response Letter for Brilinta (Ticagrelor Tablets)|
|Dec 17, 2010||AstraZeneca Receives Complete Response Letter From US FDA For Brilinta (ticagrelor Tablets)|
|Sep 15, 2010||US Food and Drug Administration Extends Review Timeline For Brilinta (Ticagrelor) New Drug Application|
|Jul 29, 2010||FDA Advisory Committee Recommended US FDA Approval of Brilinta (Ticagrelor) for Acute Coronary Syndromes|
|Nov 19, 2009||AstraZeneca Submits US New Drug Application for ticagrelor (Brilinta), an Investigational Antiplatelet Agent|
Always consult your healthcare provider to ensure the information displayed on this page applies to your personal circumstances.